Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 866.43M P/E - EPS this Y -50.00% Ern Qtrly Grth -
Income -66.07M Forward P/E -36.73 EPS next Y 106.70% 50D Avg Chg 13.00%
Sales 124.46M PEG -0.49 EPS past 5Y - 200D Avg Chg 27.00%
Dividend N/A Price/Book 7.15 EPS next 5Y 30.00% 52W High Chg -21.00%
Recommedations 1.40 Quick Ratio 4.09 Shares Outstanding 232.69M 52W Low Chg 453.00%
Insider Own 1.95% ROA -16.22% Shares Float 226.69M Beta 0.82
Inst Own 60.37% ROE -49.84% Shares Shorted/Prior 35.02M/33.61M Price 4.04
Gross Margin 57.15% Profit Margin -53.09% Avg. Volume 5,148,887 Target Price 13.65
Oper. Margin -81.44% Earnings Date May 2 Volume 10,175,200 Change 5.21%
About Ardelyx, Inc.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx, Inc. News
04/18/24 Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
04/02/24 The Millionaire’s Shortcut: 3 Stocks to Transform Your Portfolio This Month
03/28/24 Ardelyx, Inc. Reports Employment Inducement Grants
03/25/24 Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
03/21/24 Institutional investors may overlook Ardelyx, Inc.'s (NASDAQ:ARDX) recent US$195m market cap drop as long-term gains remain positive
03/16/24 The Clock is Ticking: 3 Stocks Set to Explode in the Next Quarter
02/28/24 The Millionaire’s Watchlist: 3 Stocks Set for a Meteoric Rise
02/27/24 Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
02/27/24 Stocks on the Launchpad: The Next 3 Market Sensations
02/23/24 Ardelyx, Inc. (NASDAQ:ARDX) Q4 2023 Earnings Call Transcript
02/22/24 Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say
02/22/24 Ardelyx (ARDX) Reports Q4 Loss, Lags Revenue Estimates
02/22/24 Ardelyx Inc (ARDX) Reports Robust Revenue Growth and Strategic Advances in 2023
02/22/24 Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
02/20/24 Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know
03:30 PM Analyst Upgrades: 3 Stocks Predicted to Soar In Q2 2024
12:24 PM 3 Revolutionary Biotech Stocks Poised for 10X Surge
02/15/24 Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
02/09/24 Wall Street Analysts Believe Ardelyx (ARDX) Could Rally 34.84%: Here's is How to Trade
02/09/24 Ardelyx (ARDX) Is a Great Choice for 'Trend' Investors, Here's Why
ARDX Chatroom

User Image Bluefin1976 Posted - 1 hour ago

$ARDX Look at the PM bids... how low they are. We are blowing through the 6’s fast! Going the wrong direction though!! This will easily be in the 5’s by closing.

User Image opportoni Posted - 1 hour ago

$ARDX I expect the gap at 6.16 to be closed today. Hope we will see some buying then.

User Image opportoni Posted - 3 hours ago

@bernardbaruch @Volk_Bremen The thing is: I expect this company to do better than the market and be less affected by macroeconomics. If I wanted something that does what markets do, I‘d hold 100% index ETFs and not 95% $ARDX.

User Image Food4Thought Posted - 4 hours ago

$ARDX While retail investors seem to be fussing lately, look at who is loading up for institutions and % increased since 1 April. Institutions are taking your shares if you can't stand a little volatility. ARDX has a lot less risk than after CRL, battle for delisting, FDA votes, appeals, reverse stock splits just to name a few challenges that have been overcome. 2 drugs approved, with X having chance to be SOC (Both just started selling recently). Be patent and you will be rewarded. Been with ARDX for a minute and added today for more long term hold. I feel sorry for the shorts, because once institutions allow this stock to run in positive direction , it will be the shorts who will burn (institutions just shaking trees and increasing their positions as weak retail sell). Remember institutions are always 1 step ahead of retail. ARDX has almost 10 years of patent protection, update coming from China, a growing sales force with key personnel coming over to ARDX. Sit back & chill

User Image Burning_Cash Posted - 4 hours ago

$ARDX On holiday in Phuket, so due to the time difference I'm out of the loop mostly. Just woke up and logged into my IB account to find us at 6.05 (ST has us in the 6.40s still?) and my other bios down massively as well. Haven't checked the news yet, but my guess is… Middle East? Unless WW3 is around the corner, only May 2nd matters. Still as confident as when I first bought this. Enjoy your day!

User Image Aigner_Andreas Posted - 5 hours ago

TD BUY $ARDX at 6.44, Supp 6.44 Resis 7.50 R16 HiLo 49% T1Y 6 buy 1.9 DIV N/A #Ardelyx In #stocks #trading #finance #market

User Image Cjs2027 Posted - 6 hours ago

$ARDX kelliher’s stock options have an exercise price of 7.70 usd. i am sure he signed up expecting to be in the money.

User Image Bluefin1976 Posted - 6 hours ago

$ARDX Due to the idiots in Iran, amongst others in the middle east, as well as idiots in the Biden administration, Friday is going to be a bloodbath, and WE WILL be back in the 5’s. My guess is around 5.80ish. At that point, we will be approaching the bottom… $4 to $5.

User Image aciec Posted - 6 hours ago

$ARDX Iran air defense batteries fired. Futures way down. Could be another terrible day in the market tomorrow.

User Image FerreroRocher Posted - 7 hours ago

$ARDX

User Image Hawksssss Posted - 8 hours ago

$ardx Interesting take on valuation. What’s our 10 year revenue total. I would say something like (very very very very speculative) Isbrela: 80, 150, 220, 300, 360, 420, 500, 570, 620, 700 Xphozah: 0, 120, 300, 500, 750, 1000, 1200, 1500, 1800, 2000, Total: 80, 270, 520, 800, 1110, 1420, 1770, 2120, 2420, 2700 10 year total: 13210 50% of that is 6600 mil

User Image GoingNorthTo Posted - 8 hours ago

$ARDX

User Image LagerHound Posted - 9 hours ago

$ARDX Is this pending Congessional legislation good for ArDX or not? Is there an injectable version that will be seeking fda approval? March 12, 2024 Legislation pushes for a delay in placing phosphate binders in the ESRD payment bundle ByMark E. Neuman Key takeaways: The Kidney Patient Act would delay placement of oral phosphate binders into the dialysis payment bundle. Binders would be placed in the bundle if an injectable version receives FDA approval. Congress is reviewing legislation that would delay inclusion of oral phosphate binders into the End-Stage Renal Disease Prospective Payment System bundled payment system. CMS currently has plans to include oral binders in the bundle by Jan. 1, 2025, but the Kidney Patient Act (H.R. 5074), sponsored by U.S. Rep. Earl L. “Buddy” Carter, R-Ga., would amend the American Taxpayer Relief Act of 2012 to delay inclusion of the binders until 2033.

User Image _dickhed Posted - 9 hours ago

$ARDX

User Image BigD16 Posted - 10 hours ago

$ARDX not enough catalysts in this month for bios in general. The whole sector is losing money. But with Earnings season around the corner let’s hope we start seeing a turnaround. I still think they let bios run in the hope that borrowing would get easy fro small bios in general but that’s off the table for now. LABU/ XBI are all facing the carnage. Gotta hunker down. Best of luck to all. Each to their strategy.

User Image JacksofAmerica Posted - 11 hours ago

$ARDX do we get script updates still? I've been away for a bit still holding but going to buy before earnings

User Image prodigy81 Posted - 11 hours ago

@VegasBlues I did sell $ARDX too early. I also feel this is similar movement as $ARDX. Hopefully, I have enough patience with this.

User Image Bluefin1976 Posted - 11 hours ago

$ARDX The CEO doesn’t care about the SP. He still gets his paycheck. He wants to turn Ardelyx into a BP so he can be CEO of a BP company. He will spend the money now to create a BP. If it fails.. we lose big. If he succeeds, we win big.

User Image FerreroRocher Posted - 11 hours ago

$ARDX 👏👏👏👏👏👏👏👏 https://www.linkedin.com/posts/ardelyx-inc-_save-the-date-we-will-present-first-quarter-activity-7186700068975005696-2FRR?utm_source=share&utm_medium=member_android

User Image gb2017384 Posted - 12 hours ago

$ARDX RHEEMY BABY IS HAVING A REMODELING PARTY AT ARDX WITH OUR CASH,HE DOESNT CARE IF YOU STAY OR GO BROKE,AS LONG AS HE GETS YOUR CASH $$$$$$$.

User Image ystrdys Posted - 12 hours ago

$ARDX low key this be annoying af

User Image MarkM Posted - 12 hours ago

$ARDX Apparently that gap at $6.16 *must* get filled. Almost there. This selling is ludicrous.

User Image Jizzle14 Posted - 13 hours ago

$ARDX waiting for the bounce off of $6.05, limit set...if it goes lower than 5.94, then we are in trouble short term imo.

User Image Jizzle14 Posted - 13 hours ago

@VegasBlues you took the words right out my mouth! I bought more $ARDX today 😄

User Image CMAJR69 Posted - 13 hours ago

$ARDX LOTS of spring cleaning today….

User Image Chumpchange53 Posted - 13 hours ago

$ARDX Where's the beef???

User Image VegasBlues Posted - 13 hours ago

$ARDX still here. Been here 2+ years. Not selling until min $15+ … but geez… we need an ER or two to starting showing off our revenue growth to turn this around… it’s painful lately. Buy. Hold. Chill. 🍻

User Image Timerider Posted - 13 hours ago

$ARDX Some kid half my age a pro in bio trading said shorts go out with the tide after Q1, the notorious weak Q. I was mentioning shorts ease without script info at 8.50 , I guess I missed that class at Wharton

User Image opportoni Posted - 13 hours ago

$ARDX

User Image PompousPilot Posted - 14 hours ago

$ARDX https://x.com/TonyFauci2/status/1781006471771177316

Analyst Ratings
Wedbush Outperform Apr 17, 24
Leerink Partners Outperform Apr 5, 24
Piper Sandler Overweight Feb 23, 24
Wedbush Outperform Feb 23, 24
Wedbush Outperform Jan 12, 24
Citigroup Buy Jan 10, 24
Raymond James Strong Buy Jan 9, 24
Raymond James Strong Buy Dec 18, 23
Wedbush Outperform Dec 1, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Rosenbaum David P. Chief Development Of.. Chief Development Officer Jan 08 Sell 6.64 30,000 199,200 286,596 01/10/24
Renz Justin A Chief Financial Offi.. Chief Financial Officer Dec 26 Sell 6.36 225,000 1,431,000 182,426 12/28/23
Renz Justin A Chief Financial Offi.. Chief Financial Officer Dec 26 Option 0.99 75,000 74,250 407,426 12/28/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Dec 18 Sell 6.07 5,675 34,447 316,596 12/20/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Dec 14 Sell 5.55 7,000 38,850 322,271 12/15/23
GRAMMER ELIZABETH A See Remarks See Remarks Dec 11 Sell 5.0785 50,000 253,925 275,675 12/13/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Dec 08 Sell 5.2738 20,000 105,476 329,271 12/08/23
Williams Laura A Chief Medical Office.. Chief Medical Officer Nov 20 Sell 4.3622 2,581 11,259 266,191 11/22/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Nov 20 Sell 4.36 3,767 16,424 113,293 11/22/23
Rodriguez Susan Chief Commercial Off.. Chief Commercial Officer Nov 20 Sell 4.3622 4,714 20,563 346,973 11/22/23
Renz Justin A Chief Financial Offi.. Chief Financial Officer Nov 20 Sell 4.3622 2,873 12,533 332,426 11/22/23
RAAB MICHAEL President & CEO President & CEO Nov 20 Sell 4.3622 11,368 49,589 867,868 11/22/23
GRAMMER ELIZABETH A See Remarks See Remarks Nov 20 Sell 4.3622 2,384 10,399 325,675 11/22/23
Felsch Robert Ora See Remarks See Remarks Nov 20 Sell 4.3622 1,044 4,554 117,066 11/22/23
Blanks Robert See Remarks See Remarks Nov 20 Sell 4.3622 2,835 12,367 260,453 11/22/23
Williams Laura A Chief Medical Office.. Chief Medical Officer Nov 15 Sell 3.9999 25,000 99,998 266,839 11/17/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Oct 10 Sell 4 1,644 6,576 365,378 10/12/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Sep 08 Sell 4.55 2,897 13,181 367,022 09/12/23
Williams Laura A Chief Medical Office.. Chief Medical Officer Jun 27 Sell 3.3453 25,000 83,632 294,430 06/29/23
Blanks Robert See Remarks See Remarks Jun 23 Sell 3.63 33,333 120,999 266,134 06/27/23
Blanks Robert See Remarks See Remarks Jun 23 Option 3.42 33,333 113,999 299,467 06/27/23
Rosenbaum David P. Chief Development Of.. Chief Development Officer Mar 29 Sell 4.6293 3,000 13,888 113,096 03/31/23
Felsch Robert Ora See Remarks See Remarks Aug 31 Buy .6188 3,000 1,856 91,418 09/01/22
Rosenbaum David P. Chief Development Of.. Chief Development Officer Aug 31 Buy 0.62 3,000 1,860 92,369 09/01/22
Rosenbaum David P. Chief Development Of.. Chief Development Officer Aug 31 Sell 0.92 3,000 2,760 89,369 09/01/22
Renz Justin A Chief Financial Offi.. Chief Financial Officer Aug 31 Buy 0.6188 3,000 1,856 263,549 09/01/22
Williams Laura A Chief Medical Office.. Chief Medical Officer Aug 31 Buy 0.6188 3,000 1,856 245,441 09/01/22
RAAB MICHAEL President & CEO President & CEO Aug 31 Buy 0.6188 3,000 1,856 665,680 09/01/22
GRAMMER ELIZABETH A See Remarks See Remarks Aug 31 Buy 0.6188 3,000 1,856 256,110 09/01/22
Rodriguez Susan Chief Commercial Off.. Chief Commercial Officer Aug 22 Sell 0.98 3,420 3,352 286,173 08/24/22
Rosenbaum David P. Chief Development Of.. Chief Development Officer Aug 22 Sell 0.98 1,955 1,916 89,369 08/24/22
Blanks Robert See Remarks See Remarks Aug 22 Sell 0.98 1,458 1,429 317,669 08/24/22
RAAB MICHAEL President & CEO President & CEO Aug 22 Sell 0.98 6,146 6,023 662,680 08/24/22
GRAMMER ELIZABETH A See Remarks See Remarks Aug 22 Sell 0.98 1,236 1,211 253,110 08/24/22
Williams Laura A Chief Medical Office.. Chief Medical Officer Aug 22 Sell 0.98 1,276 1,250 242,441 08/24/22
Renz Justin A Chief Financial Offi.. Chief Financial Officer Aug 22 Sell 0.98 1,498 1,468 260,549 08/24/22
Renz Justin A Chief Financial Offi.. Chief Financial Officer Jun 06 Sell 0.64 73,312 46,920 262,047 06/08/22
Rodriguez Susan Chief Commercial Off.. Chief Commercial Officer Jun 06 Sell 0.64 43,920 28,109 289,593 06/08/22
Blanks Robert See Remarks See Remarks Jun 06 Sell 0.64 73,312 46,920 324,315 06/08/22
GRAMMER ELIZABETH A See Remarks See Remarks Jun 06 Sell 0.64 60,821 38,925 254,346 06/08/22
Rosenbaum David P. Chief Development Of.. Chief Development Officer Jun 06 Sell 0.64 61,640 39,450 89,866 06/08/22
RAAB MICHAEL President & CEO President & CEO Jun 06 Sell 0.64 103,624 66,319 668,826 06/08/22
Blanks Robert See Remarks See Remarks Feb 22 Sell 0.67 1,752 1,174 399,116 02/25/22
SANDELL SCOTT D 10% Owner 10% Owner Dec 09 Sell 1.32 2,881,570 3,803,672 2,258,850 12/27/21
BASKETT FOREST 10% Owner 10% Owner Dec 09 Sell 1.32 2,881,570 3,803,672 2,258,850 12/27/21
GRAMMER ELIZABETH A See Remarks See Remarks Dec 15 Option 2.32 42,000 97,440 113,527 12/15/20
GRAMMER ELIZABETH A See Remarks See Remarks Dec 15 Sell 7.3 42,000 306,600 72,527 12/15/20